Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today issued a year-end corporate update. Among the highlights, the update discussed POAI’s November 2021 acquisition of zPREDICTA, a cutting-edge cancer based company with a proven commercial and scientific record and patented 3D cell culture platform. “zPREDICTA’s technology has been validated in multiple myeloma and cell growth. We believe this is the only human bone marrow-derived cell culture model capable of maintaining primary multiple myeloma cells. The science is now being adapted to other cancer cell cultures,” reads the update by J. Melville (“Mel”) Engle. “Besides the synergies already present with our Helomics and TumorGenesis divisions, the acquisition provides a foot in the door for POAI to large pharmaceutical customers already doing business with zPREDICTA. We now possess a ‘one-two’ punch to pharma with the established 3D cell culture platform and our CoRE(TM) artificial intelligent technology that will cut costs and time in drug discovery and drug repurposing.”
To view the full press release, visit https://ibn.fm/mlwtu
About Predictive Oncology Inc.
Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcomes. Using artificial intelligence, Predictive Oncology utilizes a database of 150,000+ cancer tumors, categorized by patient type, against drug compounds to determine optimal therapies to be used to ultimately eliminate cancer. As the drug discovery community has now realized, a genomics-based approach to cancer research and drug development is insufficient to achieve the promise of personalized therapeutics. Predictive Oncology instead takes a multiomic approach, which considers the vast multitude of factors that make each cancer unique. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.